2. Search Result
Search Result
Results for "

Angiotensin (1-7)

" in MedChemExpress (MCE) Product Catalog:

16

Inhibitors & Agonists

8

Peptides

4

Natural
Products

1

Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-12403
    Talfirastide
    Maximum Cited Publications
    17 Publications Verification

    TXA127; Angiotensin (1-7); Ang-(1-7)

    		 Angiotensin Receptor Angiotensin-converting Enzyme (ACE) Endogenous Metabolite Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
    Angiotensin 1-7 (Ang-(1-7)) is an endogenous heptapeptide from the renin-angiotensin system (RAS) with a cardioprotective role due to its anti-inflammatory and anti-fibrotic activities in cardiac cells. Angiotensin 1-7 inhibits purified canine ACE activity (IC50=0.65 μM). Angiotensin 1-7 acts as a local synergistic modulator of kinin-induced vasodilation by inhibiting ACE and releasing nitric oxide. Angiotensin 1-7 blocks Ang II-induced smooth muscle cell proliferation and hypertrophy and shows antiangiogenic and growth-inhibitory effects on the endothelium. Angiotensin 1-7 shows anti-inflammatory activity .
    Talfirastide
  • HY-P1656
    (D-Pro7)-Angiotensin I/II (1-7)
    1 Publications Verification

    		 Angiotensin Receptor Mas-related G-protein-coupled Receptor (MRGPR) Cardiovascular Disease
    (D-Pro7)-Angiotensin I/II (1-7) is a potent Mas receptor inhibitor with a Ki of 0.001 μM for rat receptors. (D-Pro7)-Angiotensin I/II (1-7) competitively blocks the binding of Angiotensin-(1-7) to the Mas receptor and attenuates the vasodilatory effect of rat aortas under physiological and hypertensive conditions. (D-Pro7)-Angiotensin I/II (1-7) can be used for studies on the function of the renin-angiotensin system and the pathological mechanisms of hypertension .
    (D-Pro7)-Angiotensin I/II (1-7)
  • HY-15778
    AVE 0991
    10+ Cited Publications

    		 Angiotensin Receptor Cardiovascular Disease Endocrinology
    AVE 0991 is a nonpeptide and orally active angiotensin-(1-7) receptor agonist with an IC50 of 21 nM .
    AVE 0991
  • HY-12403A
    Talfirastide acetate
    Maximum Cited Publications
    17 Publications Verification

    TXA127 acetate; Angiotensin (1-7) acetate; Ang-(1-7) acetate

    		 Angiotensin Receptor Angiotensin-converting Enzyme (ACE) Endogenous Metabolite Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
    Angiotensin 1-7 (Ang-(1-7)) acetate is an endogenous heptapeptide from the renin-angiotensin system (RAS) with a cardioprotective role due to its anti-inflammatory and anti-fibrotic activities in cardiac cells. Angiotensin 1-7 acetate inhibits purified canine ACE activity (IC50=0.65 μM). Angiotensin 1-7 acetate acts as a local synergistic modulator of kinin-induced vasodilation by inhibiting ACE and releasing nitric oxide. Angiotensin 1-7 acetate blocks Ang II-induced smooth muscle cell proliferation and hypertrophy and shows antiangiogenic and growth-inhibitory effects on the endothelium .
    Talfirastide acetate
  • HY-N5063
    Plantainoside D
    2 Publications Verification

    		 Angiotensin-converting Enzyme (ACE) IKK Calcium Channel PKC Reactive Oxygen Species (ROS) NF-κB Apoptosis Sirtuin NOD-like Receptor (NLR) Cardiovascular Disease Neurological Disease Inflammation/Immunology
    Plantainoside D, a phenylethanoid glycosides, is a IKK-β inhibitor with diverse biological activities. Plantainoside D shows inhibitory activity of angiotensin-converting enzyme (ACE) with an IC50 of 2.17 mM. Plantainoside D significantly reduces the release of glutamate from nerve terminals in the cerebral cortex of rats by inhibiting the voltage-dependent calcium channel (VDCCs) and protein kinase C (PKC) signaling cascade. Plantainoside D significantly alleviates cell apoptosis by inhibiting the generation of ROS and the activation of NF-κB. Plantainoside D significantly improves acute lung injury (ALI) induced by sepsis by regulating the Sirt3/NLRP3 signaling pathway. Plantainoside D can be used for the study of neuroprotection, antioxidant, anti-inflammation, antihypertension .
    Plantainoside D
  • HY-163438
    BKIDC-1553

    		Angiotensin-converting Enzyme (ACE) Cardiovascular Disease Cancer
    BKIDC-1553 is an orally active antiglycolytic agent and a bumped kinase inhibitor derived compound with a predicted ~17 h half-life in human. BKIDC-1553 inhibits CYP2C8 and Angiotensin Converting Enzyme and can be used for cancer research .
    BKIDC-1553
  • HY-133829
    Zofenoprilat

    		Angiotensin-converting Enzyme (ACE) NO Synthase Reactive Oxygen Species (ROS) Cardiovascular Disease
    Zofenoprilat is an angiotensin-converting enzyme (ACE) inhibitor with an IC50 of 1.7 nM. Zofenoprilat exerts cardioprotective and renoprotective effects by inhibiting angiotensin II expression and lowering blood pressure. Zofenoprilat promotes NO production and reduces endothelin-1 (ET-1) expression. Zofenoprilat decreases TNFα-induced ROS production and protects vascular endothelial function. Zofenoprilat regulates oxidative stress-related molecules and possesses antioxidant activity. Zofenoprilat can be used in studies related to hypertension and congestive heart failure .
    Zofenoprilat
  • HY-12403R
    Talfirastide (Standard)

    TXA127 (Standard); Angiotensin (1-7) (Standard); Ang-(1-7) (Standard)

    		 Angiotensin Receptor Angiotensin-converting Enzyme (ACE) Endogenous Metabolite Reference Standards Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
    Talfirastide (Standard) is the analytical standard of Talfirastide. This product is intended for research and analytical applications. Angiotensin 1-7 (Ang-(1-7)) is an endogenous heptapeptide from the renin-angiotensin system (RAS) with a cardioprotective role due to its anti-inflammatory and anti-fibrotic activities in cardiac cells. Angiotensin 1-7 inhibits purified canine ACE activity (IC50=0.65 μM). Angiotensin 1-7 acts as a local synergistic modulator of kinin-induced vasodilation by inhibiting ACE and releasing nitric oxide. Angiotensin 1-7 blocks Ang II-induced smooth muscle cell proliferation and hypertrophy and shows antiangiogenic and growth-inhibitory effects on the endothelium. Angiotensin 1-7 shows anti-inflammatory activity .
    Talfirastide (Standard)
  • HY-108120
    L-162537

    		Angiotensin Receptor Cardiovascular Disease
    L-162537 is a competitive human angiotensin II receptor 1 (AT1) and receptor 2 (AT2) antagonist with an IC50=1.7 nM for AT1. L-162537 inhibits Ang II-mediated vasoconstriction, blood pressure elevation and related pathological signaling pathways. L-162537 is promising for research of angiotensin II-related cardiovascular diseases such as hypertension .
    L-162537
  • HY-179277
    MIPS3526

    		Adenosine Receptor Cardiovascular Disease
    MIPS3526 is a potent and selective A2B adenosine receptor (A2BR) agonist with a pEC50 of 10.17 (EC50 of 58 pM). MIPS3526 shows highly receptor subtype selective versus the A1R, A2AR, and A3R. MIPS3526 ameliorates angiotensin II stimulating effects in both cardiac myocytes and fibroblasts. MIPS3526 can be used for the study of cardiovascular disease including heart failure where cardiac remodeling is a major driver .
    MIPS3526
  • HY-P3545
    5-Valine-angiotensin I

    		Angiotensin Receptor Cardiovascular Disease
    5-Valine-angiotensin I is an Ang I peptide belonging to angiotensin I. 5-Valine-angiotensin I induces muscle contraction, can be used for renin-angiotensin system studies. Angiotensin I is a putative neurotransmitter, is the precursor of angiotensin II and of angiotensin fragment 1-7, which are involved in regulation of fluid volume and the release of aldosterone .
    5-Valine-angiotensin I
  • HY-19200
    RB-105

    		Neprilysin Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    RB-105 is an inhibitor of angiotensin-converting enzyme (ACE) (Ki = 4.2 nM) and neutral endopeptidase (NEP) (Ki = 1.7 nM). RB-105 after inhibiting ACE reduces the production of Ang II and increase the level of bradykinin. RB-105 after inhibiting NEP increases the level of natriuretic peptide and further increases the level of bradykinin, thereby generating a powerful synergistic effect. RB-105 has significant antihypertensive and natriuretic effects in both spontaneously hypertensive rats and normal blood pressure rats. RB-105 can be used for research on hypertension .
    RB-105
  • HY-170767
    SARS-CoV-2-IN-109

    		SARS-CoV Infection
    SARS-CoV-2-IN-109 (compound 50) is an inhibitor targeting SARS-CoV with in vivo anti-infection activity. SARS-CoV-2-IN-109 targets the interaction between the SARS-CoV-2 Spike receptor-binding domain (RBD) and the human receptor angiotensin-converting enzyme 2 (ACE2) (EC50=26.5 μM), blocking the entry of SARS-CoV-2 into VeroE6 cells (EC50=17.0 μM). The CC50 of SARS-CoV-2-IN-109 for VeroE6 cells is >100 μM .
    SARS-CoV-2-IN-109
  • HY-P0216A
    A-779 TFA

    		Angiotensin Receptor Cardiovascular Disease
    A-779 TFA is a selective angiotensin-(1-7) (Ang-(1-7)) antagonist. A-779 TFA blocks Arachidonic acid release, bradykinin potentiation effects and hypotensive action. A-779 TFA exerts diuretic effects in non-pregnant rats, antidiuretic effects in late-pregnant rats, and also inhibits feed intake and water consumption in late-pregnant rats. A-779 TFA attenuates the regulatory effects of prostacyclin, nitric oxide and thromboxane A2 associated with angiotensin-(1-7). A-779 TFA can be used in studies related to hypertension .
    A-779 TFA
  • HY-167153
    PNA5

    		Interleukin Related Reactive Oxygen Species (ROS) Cardiovascular Disease Neurological Disease Inflammation/Immunology
    PNA5 is a novel, blood-brain barrier permeable glycosylated angiotensin-(1-7) peptide and MasR agonist. PNA5 inhibits IL-7, increases IL-10. PNA5 inhibits ROS generation, decreases Iba-1 expression. PNA5 exhibits sustained cognitive protective effects. PNA5 rescues blunted cerebral functional hyperemia. PNA5 can be used in the research of inflammation-related brain diseases .
    PNA5
  • HY-P11643
    LVV-hemorphin-7

    		Angiotensin Receptor Aminopeptidase DNA/RNA Synthesis Neurological Disease
    LVV-hemorphin-7 is an Angiotensin IV receptor ligand and IRAP inhibitor (IC50s: 17.6 nM for sheep adrenal IRAP; 5.0 nM for sheep cerebellum IRAP). LVV-hemorphin-7 inhibits the catalytic activity of IRAP. LVV-hemorphin-7 stimulates DNA synthesis. LVV-hemorphin-7 elicits a number of physiological effects, including cellular proliferation and memory enhancement .
    LVV-hemorphin-7

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: